4.8 Article

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 361, 期 11, 页码 1075-1080

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa0810257

关键词

-

资金

  1. Biogen [111 JC 101]
  2. Biogen Idec
  3. Bayer-Schering
  4. Merck Serono
  5. Teva-Sanofi-Aventis

向作者/读者索取更多资源

We describe the clinical and therapeutic course of a 52-year-old patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML) developed after 12 months of therapy with natalizumab. The patient was hospitalized 2 months after the onset of neurologic and psychiatric symptoms and was treated with plasma exchange and immunoadsorption to eliminate natalizumab. After a brief improvement, he became critically ill with an apparent episode of immune reconstitution inflammatory syndrome. Steroid-pulse therapy led to stabilization of the patient's condition and clinically significant recovery. This case illustrates that prompt diagnosis and treatment may improve the outcome in patients with severe PML associated with natalizumab therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据